Rui Er Group Announces Completion of $200 Million Series E Financing, with China Renaissance as Exclusive Financial Advisor

VCBeat (WeChat ID: vcbeat) has learned that Arrail Group, a leading brand in China’s high-end dental healthcare sector, announced today the completion of its Series E financing, with a total transaction value nearing USD 200 million. The round was led by Temasek, with participation from internationally renowned investors including OrbiMed, Ward Ferry, The Hina Group, Industrial Bank Co., Ltd., and Mirae Asset Financial Group. China Renaissance served again as the exclusive financial advisor to Arrail Group in this transaction, marking the fifth collaboration between China Renaissance and Arrail Group since 2010.

ARRAI, founded in 1999, pioneered the introduction of advanced international dental clinic concepts to China. It has since become a leading brand in China’s high-end oral healthcare sector. Upholding the service philosophy of “Patients as Family,” ARRAI has long been delivering high-quality, internationally standardized oral healthcare services to its clients. Currently, the group operates under two major brands: Arrail and Ruital. Driven by this dual-brand strategy, ARRAI has established over 100 dental clinics and hospitals across 16 cities in China, serving nearly 10 million patient visits cumulatively, and has forged strategic partnerships with numerous renowned enterprises.

ARRAI places great emphasis on discipline development and talent cultivation, boasting a well-established hierarchical system for dental professionals. The group has assembled renowned stomatology experts from both domestic and international institutions, primarily alumni of prestigious schools such as the UCL Eastman Dental Institute (University College London), Peking University School of Stomatology, and West China School of Stomatology (Sichuan University). Furthermore, ARRAI maintains close collaborative relationships with internationally acclaimed institutions, including the University of Pennsylvania School of Dental Medicine and the UCLA School of Dentistry. Additionally, by developing its proprietary online training platform and implementing a blended learning model that combines online and offline instruction, the group has established a mature physician training mechanism.

The oral healthcare market has become one of the fastest-growing specialty segments within China’s medical services sector. Driven by the rapid development of the Chinese economy and rising public awareness of oral health, it is expected to maintain robust growth in the coming years.

Zou Qifang, Founder and President of ARRAI, stated, “For a long time, the demand for oral healthcare services among China’s population has remained largely unmet. Currently, the domestic oral healthcare market exceeds RMB 100 billion in size, and as consumer spending power rises, public awareness of oral health will continue to grow. Since its inception, ARRAI has adhered to a customer-centric service philosophy and the principle of appropriate treatment, providing comprehensive, one-stop services throughout the entire care journey based on customer needs.”

The successful completion of this Series E financing has undoubtedly injected new momentum into Arrail’s further development. ARRAI will continue to refine its development strategy, actively expand its clinic network across China, and strive to become a benchmark enterprise in China’s dental industry, providing high-quality mid-to-high-end dental services to customers nationwide and around the world.

In 1999, ARRAI established its first high-end dental clinic, the Beijing International Tower Clinic. Upholding the service philosophy of “Customers as Family,” and backed by 22 years of development and accumulation, ARRAI has consistently delivered high-quality services and leveraged extensive expertise to help people achieve more confident smiles and a more comfortable experience. Currently, ARRAI has grown into a large-scale chain medical institution operating under two brands, “Arrail” and “Ruitai.” With a presence in major cities including Beijing, Shanghai, Shenzhen, Guangzhou, Hangzhou, Xiamen, Tianjin, Chengdu, Chongqing, Xi’an, Qingdao, Changsha, Jinan, Wuxi, and Dalian, the group operates over 100 clinics and hospitals. Having served nearly ten million patient visits to date, ARRAI provides professional, leading, and internationally standardized high-quality dental medical services.

Temasek is an investment company with a net portfolio value of S$306 billion (equivalent to RMB 1.52 trillion) as of March 31, 2020. The Temasek Charter defines our roles as investors, institutions, and stewards of assets, shaping our philosophy and mission to pursue excellence, fulfill our mandate, and benefit future generations. Our investment philosophy is guided by four key themes: transforming economies, growing middle class, strong comparative advantages, and emerging champions. We actively seek sustainable solutions to address current and future challenges, seize investment and other opportunities, and help build a better, smarter, and more sustainable world. Headquartered in Singapore, Temasek maintains 11 offices worldwide.

OrbiMed, founded in 1989, is the world’s largest investment firm dedicated exclusively to the healthcare and life sciences sectors. With over two decades of focused investment experience globally, OrbiMed’s portfolio spans biopharmaceuticals, life sciences technologies, medical devices, healthcare services, and diagnostics. Its investment activities cover all stages, from early-stage startups and growth-phase companies to mature enterprises and post-IPO entities. The investment team comprises more than 80 distinguished professionals worldwide, with expertise spanning life sciences, medicine, finance, and law. OrbiMed is committed to identifying and supporting healthcare and life sciences companies that advance human health. The firm manages approximately $13 billion in assets under management.

Ward Ferry Management (BVI) Limited (“Ward Ferry”) was established in 2000. Headquartered in Hong Kong, it is a boutique asset management firm that manages assets for global institutional investors and invests in Asian equity markets. Adhering to a value-oriented investment strategy, Ward Ferry employs bottom-up research to gain insights into industry and corporate fundamentals, upholds a long-term investment philosophy, and thereby generates sustainable returns.

TheHinaGroup is a leading investment bank and investment firm specializing in the internet economy, technology, consumer, and healthcare sectors. TheHinaGroup manages dual-currency funds in RMB and USD, encompassing venture capital funds focused on early-stage investments and new economy funds targeting growth-stage and late-stage investments. Adhering to a research-driven and value-driven approach, TheHinaGroup provides diversified value-added services to its portfolio companies, creating lasting value for both its portfolio companies and fund investors.

Xingtou Capital is the equity investment platform under the Industrial Bank Group. Adhering to the “Commercial Banking + Investment Banking” strategy, it is committed to leveraging investment banking capabilities to provide invested enterprises with comprehensive financial services, industrial resources, and other forms of empowerment, thereby supporting the transformation and development of China’s real economy. Its investment scope covers hard technology, mass consumption, big health, and other sectors.

Mirae Asset Group is the asset management arm of Mirae Asset Financial Group. As a leading independent financial services group in Asia, Mirae Asset Financial Group offers comprehensive financial services, including asset management, wealth management, investment banking, and life insurance. Currently, Mirae Asset manages assets totaling $459 billion. The Mirae Asset China team allocates investments across industries such as biopharmaceuticals, internet consumer sectors, and high-end technology manufacturing through both USD and RMB investments.

China New Economy Investment Banker of the Year, Focusing on Global TMT, Consumer, and Healthcare Sectors. Beyond investment banking services, China Renaissance is managing a RMB fund and a USD fund. The company has branches in Beijing, Shanghai, Los Angeles, and San Francisco and holds a license for the U.S. securities market. The healthcare industry is a key focus area where China Renaissance possesses significant advantages, having been ranked as the new economy investment bank with the highest number of healthcare deals in China for four consecutive years. Meanwhile, China Renaissance boasts the largest, most professional, and most comprehensively integrated healthcare investment banking team in the country.